Exploring free pregnancy associated plasma protein a (fPAPP-A) as a biomarker in early pregnancy.

First trimester Free PAPP-A Immunoassay Live birth Miscarriage PAPP-A

Journal

Practical laboratory medicine
ISSN: 2352-5517
Titre abrégé: Pract Lab Med
Pays: Netherlands
ID NLM: 101690848

Informations de publication

Date de publication:
Nov 2024
Historique:
received: 20 06 2024
revised: 16 08 2024
accepted: 15 09 2024
medline: 16 10 2024
pubmed: 16 10 2024
entrez: 16 10 2024
Statut: epublish

Résumé

In combined first trimester screening for Down syndrome, Pregnancy-Associated Plasma Protein A (PAPP-A) is pivotal. PAPP-A tests evaluate total PAPP-A, consisting of the biologically active free PAPP-A (fPAPP-A) and PAPP-A complexed with eosinophil major basic protein's proform (proMBP). While PAPP-A is well-researched, limited understanding persists regarding fPAPP-A's first trimester concentrations and diagnostic utility. and methods: PAPP-A and fPAPP-A levels were gauged in 602 serum samples at 2-week intervals (gestational weeks 4-14) from 159 women with delivery of a healthy neonate and 80 samples from 37 miscarriages. The final sample at the time of diagnosis from women who miscarried was included in analyses. During the first trimester, PAPP-A and fPAPP-A levels displayed significant and strong correlation (r = 0.94), with median values doubling weekly. Free PAPP-A constituted only 3.0 % of PAPP-A over gestational weeks. Low fPAPP-A linked to miscarriage (p < 0.001), maternal weight (p < 0.001), and smoking (p = 0.02). For miscarriage prediction fPAPP-A was equal to PAPP-A (area under the receiver operating characteristics curve 0.79 vs. 0.81, p = 0.44). Investigating fPAPP-A presence and concentration directly in first trimester serum has not been done previously. This study report lower fPAPP-A values than anticipated from prior enzymatic studies of fPAPP-A. fPAPP-A was not superior to PAPP-A as a first trimester biomarker in this dataset.

Identifiants

pubmed: 39411186
doi: 10.1016/j.plabm.2024.e00428
pii: S2352-5517(24)00074-X
pmc: PMC11474183
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e00428

Informations de copyright

© 2024 The Authors.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Jesper Friis Petersen (JF)

Department of Obstetrics and Gynecology, North Zealand Hospital, Dyrehavevej 29, 3400, Hillerød, Denmark.
Department of Clinical Medicine, University of Copenhagen, Denmark.

Vilma Tiittanen (V)

Biotechnology Unit, Department of Life Technologies, 20014, University of Turku, Finland.

Saara Wittfooth (S)

Biotechnology Unit, Department of Life Technologies, 20014, University of Turku, Finland.

Ellen Løkkegaard (E)

Department of Obstetrics and Gynecology, North Zealand Hospital, Dyrehavevej 29, 3400, Hillerød, Denmark.
Department of Clinical Medicine, University of Copenhagen, Denmark.

Lennart Jan Friis-Hansen (LJ)

Department of Clinical Biochemistry, Bispebjerg Hospital University Hospital, Nielsine Nielsens Vej 2, 2400, Copenhagen, Denmark.
Department of Clinical Medicine, University of Copenhagen, Denmark.

Classifications MeSH